What we're reading October 19, 2015: Clinton campaign leads rivals in pharma donations, lawmakers in North Carolina open to provider-led organizations and managed care, big surge in Medicare spending on hepatitis C drugs.
Pharma Has Paid Big Money to the Clinton Campaign
Data gathered by the Center for Responsive Politics shows that Hillary Clinton's campaign led the list of 2016 presidential candidates who received donations from the pharmaceutical industry. She received $164,315 in donations from the drug and medical device industries during the first 6 months of the campaign.
Read more here.
NC Lawmakers Compromise on Medicaid Reform, Let ACOs In
North Carolina might soon see the state’s Primary Care Case Management system replaced. Lawmakers in the state have agreed on a compromise that will let managed care organizations and provider-led entities to enter what has traditionally been the realm of commercial health plans. The reforms, yet to be approved by CMS, will not be implemented for several years.
Read more here.
Significant Surge in Medicare Hepatitis C Spending
With about $4.6 billion spent in the first half of 2015 alone—which nearly matches the spend during the entire year in 2014—Medicare spending on hepatitis C drugs is expected to continue its upward trajectory. “We’re all waiting to see when it plateaus or when it possibly goes back down,” said Sean Cavanaugh, director of Medicare and deputy administrator at CMS. “When will that pent-up demand be sated?”
Read more here.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen